Ladenburg - Heidelberg Pharma AG (FWB: HPHA), a clinical-stage biotech company developing innovative antibody-drug conjugates (ADCs), will be present at this year's annual meeting of the American Association for Cancer Research (AACR) will present initial efficacy data from the phase I clinical trial with the ATAC candidate HDP-101 as well as preclinical data from other active ingredient candidates from the company's own ADC technology platform.

The conference will take place from April 5th to 10th, 2024 in San Diego, California, USA.

The use of antibody-drug conjugates (ADCs), which combine the high effectiveness of cell toxins with the specificity of antibodies, has so far often been limited by side effects. One reason is the binding of the ADC (off-target tox mechanisms) that is independent of the target antigen, which, for example, is responsible for the premature release of the transported cell toxins.

The study deciphered the off-target tox mechanisms of ADCs that use amatoxins (RNA polymerase II inhibitors) as a payload, so-called ATACs. The data show that liver toxicity is caused by nonspecific uptake of ATAC into liver cells. By substituting two amino acids in the antibody (LALA mutation), which are responsible for the non-specific binding of the ATAC, the off-target toxicity could be reduced. This significantly increases the tolerability of ATACs while not compromising antitumor efficacy, resulting in an improved therapeutic window of ATACs.

Contact:

Tel: +49 6203 1009-0

Email: info@hdpharma.com

(C) 2024 Electronic News Publishing, source ENP Newswire